Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TQ0245 |
Sapacitabine
CS682,CYC682 |
Nucleoside Antimetabolite/Analog | Cell Cycle/Checkpoint; DNA Damage/DNA Repair |
Sapacitabine is a nucleoside analog prodrug with antitumor activity. | |||
T13621 |
CNDAC hydrochloride
|
Nucleoside Antimetabolite/Analog; Others; Drug Metabolite | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Metabolism; Others |
CNDAC hydrochloride 是一种核苷类似物,是沙帕他滨的代谢物。 | |||
T13621L |
CNDAC
|
Others | Others |
CNDAC, a nucleoside analog, is a major metabolite of oral drug sapacitabine. | |||
T71549 | RKS-262 | ||
RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several... |